Adverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.
dataset
posted on 2012-01-03, 01:56 authored by Luis F. López-Cortés, Rosa Ruiz-Valderas, Luis Jimenez-Jimenez, María F. González-Escribano, Almudena Torres-Cornejo, Rosario Mata, Antonio Rivero, Juan A. Pineda, Manuel Marquez-Solero, Pompeyo VicianaAdverse events or intercurrent illness throughout treatment with weekly pegIFN-α-2a (135 µg) plus oral Ribavirin (400 mg twice daily); n = 58 patients.
